Gilead Sciences, Inc. (BVL:GILD)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 606.24B +19.7% |
| Revenue (ttm) | 104.00B +5.5% |
| Net Income | -11.06B |
| EPS | -8.93 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 16.98 |
| Dividend | 11.46 (2.34%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | n/a |
| Open | 151.00 |
| Previous Close | 146.34 |
| Day's Range | 151.00 - 151.00 |
| 52-Week Range | 110.25 - 151.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Gilead Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Strong growth in HIV prevention and treatment is driven by innovative launches and robust pipeline expansion, including new oral and injectable options. Strategic acquisitions and partnerships are enhancing portfolio diversity, while disciplined capital allocation and efficiency initiatives support long-term growth despite upcoming pricing pressures.
Gilead price target raised to $175 from $155 at HSBC
HSBC analyst Morten Herholdt raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps a Buy rating on the shares. The firm adjusted targets in the…
Gilead Sciences Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing a diversified pipeline across virology, oncology, and inflammation, with multiple new launches and promising clinical data expected in the next year. Key assets include long-acting HIV regimens, novel cell therapies, ADCs, and innovative inflammation treatments.
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines.
Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo
Gilead Sciences stock was down roughly 2% on Friday alongside an FDA update concerning HIV drug Bixlenvo.
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest once-daily single tablet regimen for the treatment of HIV in adults who…
US FDA approves Gilead's once-daily combination pill for HIV treatment
The U.S. Food and Drug Administration has approved Gilead Sciences' once daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels, the co...
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment...
U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), th...
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Annual Health...
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of adult patients with unresectable, local...
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hz...
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to ...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Gilead files automatic mixed securities shelf
17:08 EDT Gilead (GILD) files automatic mixed securities shelf
Gilead price target lowered to $150 from $156 at Truist
Truist lowered the firm’s price target on Gilead (GILD) to $150 from $156 and keeps a Buy rating on the shares. Gilead delivered a clean Q2 beat and raised guidance…
Gilead price target raised to $123 from $120 at RBC Capital
RBC Capital raised the firm’s price target on Gilead (GILD) to $123 from $120 and keeps a Sector Perform rating on the shares. The company delivered a solid quarter with…
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europ...
AHF Crowns Gilead Corporate Welfare King
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
The biopharmaceutical company lowered its full-year forecast for Veklury after sales of the Covid-19 treatment fell 81% in the second quarter.
Gilead Sciences Earnings Call Transcript: Q2 2026
Base business sales grew 10% year-over-year, led by HIV, oncology, and liver disease. HIV sales rose 12%, with PrEP sales doubling and exceeding $1 billion quarterly. Raised full-year guidance for HIV and total product sales, while integrating major acquisitions and preparing for key product launches.
Gilead Sciences Earnings release: Q2 2026
Gilead Sciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Gilead Sciences Slides: Q2 2026
Gilead Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Gilead Sciences Quarterly report: Q2 2026
Gilead Sciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)
Reports Q2 revenue $7.8B, consensus $7.4B. “Gilead (GILD) delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and…